TB-500
Grade BWidely used in veterinary medicine and reported anecdotally by athletes for muscle, tendon and ligament recovery. Human clinical data is limited to small pilot studies in dermal wound healing.
Widely used in veterinary medicine and reported anecdotally by athletes for muscle, tendon and ligament recovery. Human clinical data is limited to small pilot studies in dermal wound healing.
Synthetic fragment of Thymosin Beta-4 (residues 17–23). Binds G-actin to regulate cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, and recruitment of stem and progenitor cells to injured tissue.
Educational reference only — not medical advice.
TB-500 is administered subcutaneous or intramuscular injection with an approximate systemic half-life of ~2 hours (short systemic), with sustained tissue effects. Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (2× per week loading (4 weeks), then 2–5 mg weekly maintenance) is designed to match receptor kinetics rather than plasma exposure. Synthetic fragment of Thymosin Beta-4 (residues 17–23). Binds G-actin to regulate cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, and recruitment of stem and progenitor cells to injured tissue.
Sterile technique is not optional. Use a fresh needle for every injection.
Download a printable version of this checklist to log baseline, weekly and post-cycle results.
Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.
Below are the primary references used to grade TB-500. Follow the links for full-text where available and cross-check against the current literature.
2–5 mg, 2× per week loading (4 weeks), then 2–5 mg weekly maintenance, for 6–8 week loading phase, then maintenance. Route: Subcutaneous or intramuscular injection. Timing: Any time of day; rotate injection sites. Half-life: ~2 hours (short systemic), with sustained tissue effects.
Synthetic fragment of Thymosin Beta-4 (residues 17–23). Binds G-actin to regulate cytoskeletal dynamics; promotes endothelial cell migration, angiogenesis, and recruitment of stem and progenitor cells to injured tissue.
Most users track a full 6–8 week loading phase, then maintenance cycle before judging response. Subjective changes can appear within 1–3 weeks, but objective biomarker shifts typically need the full cycle plus repeat labs.
WADA-prohibited at all times (S2 class). Research chemical; not approved for human therapeutic use.
Injection site reactions; Temporary lethargy or head rush after dosing; Long-term human safety not characterized.
Commonly combined with: BPC-157, Collagen peptides, Vitamin C. Introduce one compound at a time to preserve attribution.
Baseline and post-cycle: full blood count, comprehensive metabolic panel, and category-specific markers for regenerative peptides (see the monitoring section on this page).
Off-cycle periods let receptor sensitivity and endogenous feedback normalise. Continuous dosing without a wash-out typically produces diminishing returns and a poorer safety margin.
Further reading: Research library → · Protocols →
| Attribute | TB-500This page | BPC-157 | Retatrutide |
|---|---|---|---|
| Evidence | Grade B | Grade B | Grade A |
| Category | Regenerative | Regenerative | Metabolic |
| Best for | Soft tissue regeneration | Tissue repair, gut integrity | Triple GIP/GLP-1/glucagon agonist |
| Typical dose | 2–5 mg | 250–500 mcg | Titrated 2 mg → 4 mg → 8 mg → 12 mg |
| Frequency | 2× per week loading (4 weeks), then 2–5 mg weekly maintenance | 1–2× daily | Once weekly |
| Route | Subcutaneous or intramuscular injection | Subcutaneous or oral (gut-localized) | Subcutaneous injection |
| Legal status | WADA-prohibited at all times (S2 class). Research chemical; not approved for human therapeutic use. | Not approved by the FDA for human use. Sold as a research chemical in most jurisdictions. | Investigational; not yet FDA-approved. Currently available only via clinical trials. |
| Action | Current page | View → | View → |